Iovance Biotherapeutics Reports the First Patient Randomizing of Lifileucel in P-III Trial (TILVANCE-301) for Frontline Advanced Melanoma
Shots:
- The 1st patient has been randomized in the P-III trial evaluating lifileucel + pembrolizumab vs pembrolizumab monotx. in 670 patients with frontline advanced melanoma
- The results from cohort 1A of the (IOV-COM-202) trial showed an ORR (67%) with the durability of response & remained consistent in ~20 patients. In Nov 2021, the clinical results showed that TIL cell therapy + pembrolizumab in immune-checkpoint inhibitor naïve patients showed ORR (57%) in Cervical Cancer, 60% in Melanoma with 30% CR & 39% in Head & Neck Cancer
- The Iovance TIL platform showed promising clinical data across multiple solid tumors. The US FDA granted Priority Review for lifileucel in post-anti-PD-1 melanoma with an anticipated PDUFA on Nov 25, 2023
Ref: GlobeNewswire | Image: Iovance
Related News:- Iovance Biotherapeutics Reports the US FDA Acceptance of BLA for Lifileucel to Treat Advanced Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
